BIOTHERAPEUTICS DISCOVERY
Transformational technologies to design, construct, and optimize biotherapeutics
- Informed protein design optimizes molecular properties resulting in superior efficacy, pharmacokinetics, pharmacodynamics, safety, manufacturability and differentiations
Bioconjugation technologies
- Novel approaches that enhance antibody function or improve site-specific bioconjugation
Combinatorial biologics such as bi-specific and multi-functional platforms with promising biophysical and manufacturing properties
Structure-based and computational design of therapeutics
- Novel technologies to rationally design antibody, protein and peptide therapeutics that display superior pharmaceutical properties (including selectivity, half-life extension, stability, formulatability)
Technologies that enhance multi-transmembrane protein target expression/presentation for antibody generation and screening
Technologies and patient sample access for antibody discovery from human antibody responses
Targeted delivery technologies that address/overcome cell membrane penetration, cross blood brain barrier
Technologies that can significantly enhance general protein expression, purification, stability for discovery
Integrated service providers to support early discovery activities for development of therapeutics
Broadly applicable platforms to enhance speed/quality of antibody generation
Novel biologics, combination therapies, and “biobetters” that fit Pfizer strategies